Advances in Cancer Immunotherapy: A Comprehensive Review of Current and Future Approaches in the Treatment of Solid and Hematologic Tumors..

Abstract

Cancer immunotherapy uses the patient's immune system to fight cancerous cells with little to no side effects, making it a viable treatment option for solid and hematologic cancers. Reviewing current developments as well as potential directions for the field of cancer immunotherapy, this paper focuses on immune checkpoint inhibitors (ICI), chimeric antigen receptor (CAR) T-cell treatment, and cancer vaccines. A thorough analysis of the literature using publications from 2018 to 2023 was carried out using PubMed, Scopus, and Google Scholar. The findings demonstrate the immune checkpoint inhibitors' outstanding effectiveness in treating a variety of cancers, especially when combined with anti-PD-1 and anti-CTLA-4 antibodies, which result in improved survival rates and long-lasting effects. In hematologic malignancies, CAR T-cell therapy—particularly second-generation designs—has shown encouraging results, producing notable responses in patients with relapsed or resistant illness. Cancer vaccines that target tumor-specific antigens have shown promise in enhancing T-cell responses, despite obstacles such autoreactive immune responses and tumor heterogeneity. Notwithstanding these developments, there are still several drawbacks, such as immune-related adverse effects, inconsistent response rates, and logistical challenges. According to future views, in order to overcome these obstacles and improve treatment success, new combination treatments, biomarker-driven strategies, and creative delivery methods are necessary.

Keywords:

Cancer, Immunotherapy, Hematologic Tumors

References

De Andrade, Lucas Ferrari et al. 2018. “Antibody-Mediated Inhibition of MICA and MICB Shedding Promotes NK Cell-Driven Tumor Immunity.” Science 359(6383): 1537–42. https://www.science.org/doi/10.1126/science.aao0505 (February 23, 2024).

Baird, John H. et al. 2021. “CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR–Refractory Large B-Cell Lymphoma.” Blood 137(17): 2321–25.

Böttcher, Jan P. et al. 2018. “NK Cells Stimulate Recruitment of CDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.” Cell 172(5): 1022-1037.e14.

Cabrita, Rita et al. 2020. “Tertiary Lymphoid Structures Improve Immunotherapy and Survival in Melanoma.” Nature 2020 577:7791 577(7791): 561–65. https://www.nature.com/articles/s41586-019-1914-8 (February 23, 2024).

Cercek, Andrea et al. 2022. “PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer.” New England Journal of Medicine 386(25): 2363–76.

Chen, Robert et al. 2019. “Pembrolizumab in Relapsed or Refractory Hodgkin Lymphoma: 2-Year Follow-up of KEYNOTE-087.” Blood 134(14): 1144–53.

Chiang, Eugene Y., and Ira Mellman. 2022. “TIGIT-CD226-PVR Axis: Advancing Immune Checkpoint Blockade for Cancer Immunotherapy.” Journal for ImmunoTherapy of Cancer 10(4).

Cho, Byoung Chul et al. 2022. “Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as a First-Line Treatment for PD-L1-Selected Non-Small-Cell Lung Cancer (CITYSCAPE): Primary and Follow-up Analyses of a Randomised, Double-Blind, Phase 2 Study.” The Lancet Oncology 23(6): 781–92.

Cohen, Ezra E.W. et al. 2019. “Pembrolizumab versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomised, Open-Label, Phase 3 Study.” The Lancet 393(10167): 156–67.

Costa, Luciano J. et al. 2022. “Comparison of Cilta-Cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma.” Clinical Lymphoma, Myeloma and Leukemia 22(5): 326–35.

Crump, Michael et al. 2017. “Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from the International SCHOLAR-1 Study.” Blood 130(16): 1800–1808.

D’Angelo, Sandra P. et al. 2021. “First-Line Avelumab in a Cohort of 116 Patients with Metastatic Merkel Cell Carcinoma (JAVELIN Merkel 200): Primary and Biomarker Analyses of a Phase II Study.” Journal for ImmunoTherapy of Cancer 9(7).

Dede, Zeynep, Kader Tumer, Tugce Kan, and Burcu Yucel. 2023. “Current Advances and Future Prospects in Cancer Immunotherapeutics.” Medeniyet Medical Journal 38(1): 88. /pmc/articles/PMC10064104/ (February 22, 2024).

Dobosz, Paula, and Tomasz Dzieciątkowski. 2019. “The Intriguing History of Cancer Immunotherapy.” Frontiers in Immunology 10.

Ferlay, Jacques et al. 2021. “Cancer Statistics for the Year 2020: An Overview.” International Journal of Cancer 149(4): 778–89. https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.33588 (February 22, 2024).

Flinn, Ian W. et al. 2021. “A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM Platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL).” Blood 138(Supplement 1): 740–740.

Fraune, Christoph et al. 2020. “High Homogeneity of MMR Deficiency in Ovarian Cancer.” Gynecologic Oncology 156(3): 669–75.

Gauthier, Jordan et al. 2021. “Factors Associated with Outcomes after a Second CD19-Targeted CAR T-Cell Infusion for Refractory B-Cell Malignancies.” Blood 137(3): 323–35.

Helmink, Beth A. et al. 2020. “B Cells and Tertiary Lymphoid Structures Promote Immunotherapy Response.” Nature 2020 577:7791 577(7791): 549–55. https://www.nature.com/articles/s41586-019-1922-8 (February 23, 2024).

Hollern, Daniel P. et al. 2019. “B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer.” Cell 179(5): 1191-1206.e21. https://doi.org/10.1016/j.cell.2019.10.028.

Horn, Leora et al. 2018. “First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.” New England Journal of Medicine 379(23): 2220–29.

Hu, Zhuting et al. 2021. “Personal Neoantigen Vaccines Induce Persistent Memory T Cell Responses and Epitope Spreading in Patients with Melanoma.” Nature Medicine 2021 27:3 27(3): 515–25. https://www.nature.com/articles/s41591-020-01206-4 (February 23, 2024).

Hui, Enfu et al. 2017. “T Cell Costimulatory Receptor CD28 Is a Primary Target for PD-1-Mediated Inhibition.” Science 355(6332): 1428–33.

Hunter, Bradley D., Michael Rogalski, and Caron A. Jacobson. 2019. “Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas: Efficacy, Toxicity, and Comparative Chimeric Antigen Receptor Products.” Expert Opinion on Biological Therapy 19(11): 1157–64.

Jackson, Zachary et al. 2020. “Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-Hodgkin Lymphoma.” Frontiers in Immunology 11.

Jacobson, Caron A., Jason R. Westin, et al. 2020. “Abstract CT055: Phase 1/2 Primary Analysis of ZUMA-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination With Atezolizumab (Atezo) for the Treatment of Patients (Pts) with Refractory Diffuse Large B Cell Lymphoma (DLBCL).” Cancer Research 80(16_Supplement): CT055–CT055.

Jacobson, Caron A., Bradley D. Hunter, et al. 2020. “Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.” Journal of Clinical Oncology 38(27): 3095–3106.

Jain, Michael D. et al. 2021. “Tumor Interferon Signaling and Suppressive Myeloid Cells Are Associated with CAR T-Cell Failure in Large B-Cell Lymphoma.” Blood 137(19): 2621–33.

Jenkins, Russell W., David A. Barbie, and Keith T. Flaherty. 2018. “Mechanisms of Resistance to Immune Checkpoint Inhibitors.” British Journal of Cancer 118(1): 9–16.

Kamphorst, Alice O. et al. 2017. “Rescue of Exhausted CD8 T Cells by PD-1-Targeted Therapies Is CD28-Dependent.” Science 355(6332): 1423–27.

Larkin, James et al. 2015. “Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.” New England Journal of Medicine 373(1): 23–34.

Lenz, Heinz Josef et al. 2022. “First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/ Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.” Journal of Clinical Oncology 40(2): 161–70.

Liu, Jian et al. 2022. “Cancer Vaccines as Promising Immuno-Therapeutics: Platforms and Current Progress.” Journal of Hematology & Oncology 2022 15:1 15(1): 1–26. https://link.springer.com/articles/10.1186/s13045-022-01247-x (February 23, 2024).

Locke, Frederick L. et al. 2020. “Tumor Burden, Inflammation, and Product Attributes Determine Outcomes of Axicabtagene Ciloleucel in Large B-Cell Lymphoma.” Blood Advances 4(19): 4898–4911.

———. 2022. “Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.” New England Journal of Medicine 386(7): 640–54.

Maude, Shannon L. et al. 2018. “Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.” New England Journal of Medicine 378(5): 439–48.

Mettu, Niharika B. et al. 2022. “A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.” Clinical Cancer Research 28(5): 882–92.

Miller, Kimberly D. et al. 2022. “Cancer Treatment and Survivorship Statistics, 2022.” CA: A Cancer Journal for Clinicians 72(5): 409–36. https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21731 (February 22, 2024).

Motzer, Robert J. et al. 2019. “Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.” New England Journal of Medicine 380(12): 1103–15.

Munshi, Nikhil C. et al. 2021. “Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.” New England Journal of Medicine 384(8): 705–16.

Niu, J. et al. 2022. “First-in-Human Phase 1 Study of the Anti-TIGIT Antibody Vibostolimab as Monotherapy or with Pembrolizumab for Advanced Solid Tumors, Including Non-Small-Cell Lung Cancer☆.” Annals of Oncology 33(2): 169–80.

Peng, Miao et al. 2019. “Neoantigen Vaccine: An Emerging Tumor Immunotherapy.” Molecular Cancer 2019 18:1 18(1): 1–14. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-1055-6 (February 22, 2024).

Peterson, Chelsea, Nathan Denlinger, and Yiping Yang. 2022. “Recent Advances and Challenges in Cancer Immunotherapy.” Cancers 2022, Vol. 14, Page 3972 14(16): 3972. https://www.mdpi.com/2072-6694/14/16/3972/htm (February 22, 2024).

Petitprez, Florent et al. 2020. “B Cells Are Associated with Survival and Immunotherapy Response in Sarcoma.” Nature 2020 577:7791 577(7791): 556–60. https://www.nature.com/articles/s41586-019-1906-8 (February 23, 2024).

PM Forde, JE Chaft, DM Pardoll. 2018. “Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.” N. Engl. J. Med. 379: e14.

Rosenberg, Steven A. et al. 2008. “Adoptive Cell Transfer: A Clinical Path to Effective Cancer Immunotherapy.” Nature Reviews Cancer 8(4): 299–308.

Sautès-Fridman, Catherine, Florent Petitprez, Julien Calderaro, and Wolf Herman Fridman. 2019. “Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy.” Nature Reviews Cancer 2019 19:6 19(6): 307–25. https://www.nature.com/articles/s41568-019-0144-6 (February 23, 2024).

Schneider, Dina et al. 2021. “Trispecific CD19-CD20-CD22-Targeting DuoCAR-T Cells Eliminate Antigen-Heterogeneous B Cell Tumors in Preclinical Models.” Science Translational Medicine 13(586).

Schuster, Stephen J. et al. 2019. “Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.” New England Journal of Medicine 380(1): 45–56.

———. 2021. “Long-Term Clinical Outcomes of Tisagenlecleucel in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (JULIET): A Multicentre, Open-Label, Single-Arm, Phase 2 Study.” The Lancet Oncology 22(10): 1403–15.

Shah, Bijal D. et al. 2021. “KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-Label, Multicentre ZUMA-3 Study.” The Lancet 398(10299): 491–502.

Shah, Nirali N. et al. 2020. “CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results from a Phase I Anti-CD22 CAR T-Cell Trial.” Journal of Clinical Oncology 38(17): 1938–50.

Sharma, Naveen, Jean Vacher, and James P. Allison. 2019. “TLR1/2 Ligand Enhances Antitumor Efficacy of CTLA-4 Blockade by Increasing Intratumoral Treg Depletion.” Proceedings of the National Academy of Sciences of the United States of America 116(21): 10453–62.

Spira, Alexander et al. 2021. “Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies.” Targeted Oncology 16(4): 461–69. https://link.springer.com/article/10.1007/s11523-021-00813-6 (February 23, 2024).

Van Der Stegen, Sjoukje J.C., Mohamad Hamieh, and Michel Sadelain. 2015. “The Pharmacology of Second-Generation Chimeric Antigen Receptors.” Nature Reviews Drug Discovery 14(7): 499–509.

Thommen, Daniela S. et al. 2018. “A Transcriptionally and Functionally Distinct PD-1+ CD8+ T Cell Pool with Predictive Potential in Non-Small-Cell Lung Cancer Treated with PD-1 Blockade.” Nature Medicine 2018 24:7 24(7): 994–1004. https://www.nature.com/articles/s41591-018-0057-z (February 23, 2024).

Vercellino, Laetitia et al. 2020. “Predictive Factors of Early Progression after CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.” Blood Advances 4(22): 5607–15.

Waldman, Alex D., Jill M. Fritz, and Michael J. Lenardo. 2020. “A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice.” Nature Reviews Immunology 20(11): 651–68.

Wang, Shuyue, Kun Xie, and Tengfei Liu. 2021. “Cancer Immunotherapies: From Efficacy to R